First Pavlov State Medical University

Saint, Russia

First Pavlov State Medical University

Saint, Russia
SEARCH FILTERS
Time filter
Source Type

Desrosiers A.,Yale University | Blokhina E.,First Pavlov State Medical University | Krupitsky E.,Saint Petersburg State University | Zvartau E.,First Pavlov State Medical University | And 2 more authors.
Drug and Alcohol Dependence | Year: 2017

Background The Russian Federation is experiencing a very high rate of HIV infection among people who inject drugs (PWID). However, few studies have explored characteristics of people with co-occurring opioid use disorders and HIV, including psychiatric symptom presentations and how these symptoms might relate to quality of life. The current study therefore explored a.) differences in baseline psychiatric symptoms among HIV+ and HIV- individuals with opioid use disorder seeking naltrexone treatment at two treatment centers in Saint Petersburg, Russia and b.) associations between psychiatric symptom constellations and quality of life. Methods Participants were 328 adults enrolling in a randomized clinical trial evaluating outpatient treatments combining naltrexone with different drug counseling models. Psychiatric symptoms and quality of life were assessed using the Brief Symptom Inventory and The World Health Organization Quality of Life-BREF, respectively. Results Approximately 60% of participants were HIV+. Those who were HIV+ scored significantly higher on BSI anxiety, depression, psychoticism, somatization, paranoid ideation, phobic anxiety, obsessive-compulsive, and GSI indexes (all p < 0.05) than those HIV-. A K-means cluster analysis identified three distinct psychiatric symptom profiles; the proportion of HIV+ was significantly greater and quality of life indicators were significantly lower in the cluster with the highest psychiatric symptom levels. Conclusion Higher levels of psychiatric symptoms and lower quality of life indicators among HIV+ (compared to HIV-) individuals injecting drugs support the potential importance of combining interventions that target improving psychiatric symptoms with drug treatment, particularly for HIV+ patients. © 2017 Elsevier B.V.


As the Prix Galien Russia (PGR) ceremony coincides with World HIV Day, the PGR committee has decided to distinguish Dmitry A. Lioznov, Edwin E. Zvartau, Evgeny M. Krupitsky, George E.Woody, and Jeffrey H.Samet for their research on the prevalence of HIV in vulnerable and special populations of the Russian Federation. Frederic Boucheseiche, General Secretary of Prix Galien Russia, declared: "We hope that these special awards from the PGR committee will contribute to making this unique research program and its outcomes better known to the medical and scientific community both in Russia and the world. We believed that it was important on World HIV Day to highlight research that included in-depth work with some of the most vulnerable groups suffering from addiction." 1)Dmitry A. Lioznov / Head, Department of Infectious Diseases and Epidemiology, First Pavlov State Medical University 2)Edwin E. Zvartau / M.D., Ph.D., D.Med.Sci., Professor, Head, Department of Pharmacology; Director, Valdman Institute of Pharmacology, First Pavlov State Medical University 3)Evgeny M. Krupitsky / Chief, Lab of Clinical Pharmacology of Addictions, St. Petersburg State Pavlov Medical University; Chief, Department of Addictions, St. Petersburg Bekhterev Research Psychoneurological Institute 4)George E.Woody / Professor, Department of Psychiatry; Perelman School of Medicine at the University of PA See more at: http://prixgalienrussia.com/en/komitet-prix-galien-russia-nagradit-spetsialnoy-premiey-5-uchenyih-vo-vsemirnyiy-den-borbyi-so-spidom/


PubMed | Saint Petersburg State University, Yale University and First Pavlov State Medical University
Type: | Journal: Drug and alcohol dependence | Year: 2017

The Russian Federation is experiencing a very high rate of HIV infection among people who inject drugs (PWID). However, few studies have explored characteristics of people with co-occurring opioid use disorders and HIV, including psychiatric symptom presentations and how these symptoms might relate to quality of life. The current study therefore explored a.) differences in baseline psychiatric symptoms among HIV+ and HIV- individuals with opioid use disorder seeking naltrexone treatment at two treatment centers in Saint Petersburg, Russia and b.) associations between psychiatric symptom constellations and quality of life.Participants were 328 adults enrolling in a randomized clinical trial evaluating outpatient treatments combining naltrexone with different drug counseling models. Psychiatric symptoms and quality of life were assessed using the Brief Symptom Inventory and The World Health Organization Quality of Life-BREF, respectively.Approximately 60% of participants were HIV+. Those who were HIV+ scored significantly higher on BSI anxiety, depression, psychoticism, somatization, paranoid ideation, phobic anxiety, obsessive-compulsive, and GSI indexes (all p<0.05) than those HIV-. A K-means cluster analysis identified three distinct psychiatric symptom profiles; the proportion of HIV+ was significantly greater and quality of life indicators were significantly lower in the cluster with the highest psychiatric symptom levels.Higher levels of psychiatric symptoms and lower quality of life indicators among HIV+ (compared to HIV-) individuals injecting drugs support the potential importance of combining interventions that target improving psychiatric symptoms with drug treatment, particularly for HIV+ patients.


Berezina A.,German Textile Research Center North - West | Belyaeva O.,North State Medical University | Berkovich O.,First Pavlov State Medical University | Baranova E.,First Pavlov State Medical University | And 5 more authors.
BioMed Research International | Year: 2015

Objective. To assess prevalence of metabolically healthy individuals among patients with abdominal obesity (AO) and to determine phenotype and potential genetic traits associated with a benign metabolic status. Methods. 503 AO patients without cardiovascular diseases were examined. Waist circumference (WC), BMI, blood pressure, plasma glucose and serum insulin levels, HOMA-IR, lipid profile, and adiponectin (AN) and leptin (LEP) concentrations in serum were measured. Polymorphisms A19G and Q223R of the LEP and LEP receptor gene, and G276T and T45G of the AN gene were investigated. Results. 91.3% of patients were metabolically unhealthy obese (MUO), and 8.7% metabolically healthy obese (MHO). MHO patients were younger, and had lesser BMI and WC, while duration of obesity, frequency, and duration of physical training were greater than MUO patients p < 0.05. In MHO and MUO patients distribution of the G19G, G19A, and A19A genotypes of the LEP gene and G276G, G276T, and T276T genotypes of AN gene did not differ. The T45T genotype was associated with increase of metabolic disorders' risk for patients with AO (OR = 2.331; 95% CI = 1.121 ÷ 5.132). Conclusions. Prevalence of MHO individuals among patients with AO is low. Benign metabolic status was associated with younger age, lower waist circumference, and higher physical activity, shorter duration of obesity, and G45G adiponectin genotype carriage. © 2015 A. Berezina et al.

Loading First Pavlov State Medical University collaborators
Loading First Pavlov State Medical University collaborators